Compare

Lexaria Bioscience Corp. vs BioXcel Therapeutics, Inc. vs Onconetix, Inc. vs Vaccinex, Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearLexaria Bioscience Corp.
LEXX
BioXcel Therapeutics, Inc.
BTAIQ
Onconetix, Inc.
ONCO
Vaccinex, Inc.
VCNXLast annual report: year ended 2024-12-31
Year ended2025-08-312025-12-312025-12-312024-12-31
Revenue$705.9K$642.0K$815.4K$601.0K
Revenue growth (YoY)+52.0%-71.7%-67.7%+5.4%
Gross margin99.6%74.5% (computed)77.6%n/a
Operating marginn/mn/mn/mn/m
Net marginn/mn/mn/mn/m
Net income-$11.90M-$69.90M-$14.03M-$18.63M
EPS (Diluted)-$0.66-$5.73-$16.56-$8.88
Operating cash flow-$10.45M-$57.62M-$9.68M-$16.19M
Free cash flow-$10.48M-$57.62Mn/a-$16.21M
Cash & equivalentsn/a$28.41Mn/a$1.11M
Total assets$4.18M$44.92M$24.93M$2.60M
Total liabilities$1.57M$140.38M$9.16M$5.08M
Shareholders' equity$2.99M-$95.46M$15.76M-$2.49M
Return on year-end equity-398.1%n/a-89.0%n/a
Shares outstanding19.56M22.33M1.56M2.68M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearLexaria Bioscience Corp.BioXcel Therapeutics, Inc.Onconetix, Inc.Vaccinex, Inc.
Latest$705.9K
Ended 2025-08-31
$642.0K
Ended 2025-12-31
$815.4K
Ended 2025-12-31
$601.0K
Ended 2024-12-31
1 year earlier$464.3K
Ended 2024-08-31
$2.27M
Ended 2024-12-31
$2.52M
Ended 2024-12-31
$570.0K
Ended 2023-12-31
2 years earlier$226.2K
Ended 2023-08-31
$1.38M
Ended 2023-12-31
$58.5K
Ended 2023-12-31
$275.0K
Ended 2022-12-31
3 years earlier$255.4K
Ended 2022-08-31
$375.0K
Ended 2022-12-31
n/a$900.0K
Ended 2021-12-31
4 years earlier$722.7K
Ended 2021-08-31
n/an/a$625.0K
Ended 2020-12-31